Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals

Antibody drug conjugates (ADCs) are a new class of targeted anti-cancer therapies that combine a monoclonal tumor surface receptor-targeting antibody with a highly cytotoxic molecule payload. They enable delivery of cytotoxic therapy more directly to tumor cells and minimize delivery to healthy tiss...

Descripción completa

Detalles Bibliográficos
Autores principales: McNamara, Blair, Chang, Yifan, Goreshnik, Ashley, Santin, Alessandro D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474218/
https://www.ncbi.nlm.nih.gov/pubmed/37663226
http://dx.doi.org/10.2147/IJWH.S400537
_version_ 1785100444553445376
author McNamara, Blair
Chang, Yifan
Goreshnik, Ashley
Santin, Alessandro D
author_facet McNamara, Blair
Chang, Yifan
Goreshnik, Ashley
Santin, Alessandro D
author_sort McNamara, Blair
collection PubMed
description Antibody drug conjugates (ADCs) are a new class of targeted anti-cancer therapies that combine a monoclonal tumor surface receptor-targeting antibody with a highly cytotoxic molecule payload. They enable delivery of cytotoxic therapy more directly to tumor cells and minimize delivery to healthy tissues. This review summarizes the existing literature about ADC therapies approved for use in gynecologic malignancies, relevant preclinical studies, as well as ongoing clinical trials.
format Online
Article
Text
id pubmed-10474218
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104742182023-09-03 Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals McNamara, Blair Chang, Yifan Goreshnik, Ashley Santin, Alessandro D Int J Womens Health Review Antibody drug conjugates (ADCs) are a new class of targeted anti-cancer therapies that combine a monoclonal tumor surface receptor-targeting antibody with a highly cytotoxic molecule payload. They enable delivery of cytotoxic therapy more directly to tumor cells and minimize delivery to healthy tissues. This review summarizes the existing literature about ADC therapies approved for use in gynecologic malignancies, relevant preclinical studies, as well as ongoing clinical trials. Dove 2023-08-28 /pmc/articles/PMC10474218/ /pubmed/37663226 http://dx.doi.org/10.2147/IJWH.S400537 Text en © 2023 McNamara et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
McNamara, Blair
Chang, Yifan
Goreshnik, Ashley
Santin, Alessandro D
Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals
title Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals
title_full Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals
title_fullStr Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals
title_full_unstemmed Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals
title_short Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals
title_sort value of antibody drug conjugates for gynecological cancers: a modern appraisal following recent fda approvals
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474218/
https://www.ncbi.nlm.nih.gov/pubmed/37663226
http://dx.doi.org/10.2147/IJWH.S400537
work_keys_str_mv AT mcnamarablair valueofantibodydrugconjugatesforgynecologicalcancersamodernappraisalfollowingrecentfdaapprovals
AT changyifan valueofantibodydrugconjugatesforgynecologicalcancersamodernappraisalfollowingrecentfdaapprovals
AT goreshnikashley valueofantibodydrugconjugatesforgynecologicalcancersamodernappraisalfollowingrecentfdaapprovals
AT santinalessandrod valueofantibodydrugconjugatesforgynecologicalcancersamodernappraisalfollowingrecentfdaapprovals

Ejemplares similares